X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE GLENMARK PHARMA TTK HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 51.5 11.9 431.9% View Chart
P/BV x 9.5 3.2 301.1% View Chart
Dividend Yield % 0.3 0.4 79.9%  

Financials

 TTK HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
GLENMARK PHARMA
Mar-17
TTK HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs663993 66.8%   
Low Rs399729 54.7%   
Sales per share (Unadj.) Rs535.6325.5 164.5%  
Earnings per share (Unadj.) Rs15.939.3 40.6%  
Cash flow per share (Unadj.) Rs20.048.7 41.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.2 324.2%  
Book value per share (Unadj.) Rs137.6159.2 86.4%  
Shares outstanding (eoy) m7.77282.17 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.02.6 37.5%   
Avg P/E ratio x33.321.9 152.0%  
P/CF ratio (eoy) x26.517.7 149.9%  
Price / Book Value ratio x3.95.4 71.4%  
Dividend payout %25.15.1 492.8%   
Avg Mkt Cap Rs m4,127242,991 1.7%   
No. of employees `0001.713.0 13.2%   
Total wages/salary Rs m60716,408 3.7%   
Avg. sales/employee Rs Th2,436.77,083.9 34.4%   
Avg. wages/employee Rs Th355.21,265.4 28.1%   
Avg. net profit/employee Rs Th72.5855.1 8.5%   
INCOME DATA
Net Sales Rs m4,16291,857 4.5%  
Other income Rs m61374 16.4%   
Total revenues Rs m4,22392,230 4.6%   
Gross profit Rs m19720,367 1.0%  
Depreciation Rs m322,644 1.2%   
Interest Rs m302,373 1.3%   
Profit before tax Rs m19715,724 1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m733,827 1.9%   
Profit after tax Rs m12411,088 1.1%  
Gross profit margin %4.722.2 21.4%  
Effective tax rate %37.024.3 152.1%   
Net profit margin %3.012.1 24.7%  
BALANCE SHEET DATA
Current assets Rs m1,62968,746 2.4%   
Current liabilities Rs m1,05827,027 3.9%   
Net working cap to sales %13.745.4 30.2%  
Current ratio x1.52.5 60.5%  
Inventory Days Days3085 35.0%  
Debtors Days Days3496 35.2%  
Net fixed assets Rs m55624,132 2.3%   
Share capital Rs m78282 27.5%   
"Free" reserves Rs m87844,643 2.0%   
Net worth Rs m1,06944,925 2.4%   
Long term debt Rs m15945,363 0.3%   
Total assets Rs m2,399117,639 2.0%  
Interest coverage x7.67.6 99.4%   
Debt to equity ratio x0.11.0 14.7%  
Sales to assets ratio x1.70.8 222.1%   
Return on assets %6.411.4 56.0%  
Return on equity %11.624.7 46.9%  
Return on capital %18.519.1 96.4%  
Exports to sales %0.80-   
Imports to sales %1.40-   
Exports (fob) Rs m33NA-   
Imports (cif) Rs m58NA-   
Fx inflow Rs m3356,152 0.1%   
Fx outflow Rs m638,084 0.8%   
Net fx Rs m-3048,068 -0.1%   
CASH FLOW
From Operations Rs m1276,574 1.9%  
From Investments Rs m-146-7,124 2.0%  
From Financial Activity Rs m225,432 0.4%  
Net Cashflow Rs m31,992 0.1%  

Share Holding

Indian Promoters % 65.4 48.3 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 5.2 34.4 15.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 10.5 245.7%  
Shareholders   12,723 56,727 22.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare TTK HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Feb 16, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 8-QTR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS